|
Sepsis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, we summarized the studies investigating the role and impact of modulated PCSK9 levels in inflammation, specifically in sepsis, rheumatoid arthritis and other chronic inflammatory conditions.
|
30914377 |
2019 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This has important implications in health as strategies aimed at inhibiting PCSK9 function may be an effective treatment option for both Gram-positive and negative sepsis.
|
31332258 |
2019 |
|
Sepsis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the association between presence of two genetic PCSK9 LOF variants and risk of infection and sepsis in community-dwelling adults.
|
30726226 |
2019 |
|
Sepsis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of several studies have suggested that infections and sepsis, either bacterial or viral, might be associated with elevated plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
|
31635200 |
2019 |
|
Sepsis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whether PCSK9 genotype influences long-term outcomes in sepsis survivors is unknown.
|
30473376 |
2018 |
|
Sepsis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low LDL levels per se are not simply associated with decreased sepsis survival because lowering LDL levels by inhibiting LDL production (statin treatment) is associated with adverse outcomes, while increased LDL clearance (PCSK9 loss-of-function genotype) is associated with improved outcomes in patients with low VAT/SAT.
|
29510719 |
2018 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The implication of the LDLR in the clearance of pathogenic bacterial debris in mice and human puts in perspective a new role for PCSK9 in the regulation of sepsis.
|
29342010 |
2018 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study characterizes an LDL-dependent and LDLR-mediated bacterial lipid uptake pathway regulated by PCSK9, and provides evidence in support of PCSK9 inhibition as a potential therapeutic strategy for sepsis.
|
30002483 |
2018 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These possible pleiotropic effects of PCSK9 inhibitors need further research, as they may affect cardiovascular risk and provide further insights in the development of atherosclerosis and other diseases such as Alzheimer's disease or chronic viral infection and sepsis.
|
29994840 |
2018 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, it has been suggested that inhibition of PCSK9 might also improve outcomes in mice and humans with sepsis, possibly by increasing LDLR-mediated clearance of endotoxins.
|
28600283 |
2017 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCSK9 inhibition may have other applications because it reduces inflammation and sepsis in a LDLR-dependent manner.
|
27920219 |
2017 |
|
Sepsis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
First, PCSK9 is associated with increased plasma cholesterol levels, which might be protective during sepsis.
|
28063230 |
2017 |